Mucin O -Glycans Facilitate Symbiosynthesis to Maintain Gut Immune Homeostasis

Background: The dysbiosis of gut microbiota has been implicated in the pathogenesis of inflammatory bowel diseases (IBDs); however, the underlying mechanisms have not yet been elucidated. Heavily glycosylated mucin not only establishes a first-line barrier against pathogens, but also serves as a niche for microbial growth. Methods: To elucidate relationships between dysbiosis, abnormal mucin utilization, and microbial metabolic dysfunction, we analyzed short-chain fatty acids (SCFAs) and mucin components in the stool samples of 40 healthy subjects, 49 ulcerative colitis (UC) patients, and 44 Crohn's disease (CD) patients from Japan. Findings: The levels of n-butyrate were significantly lower in the stools of both the CD and UC patients than in those of the healthy subjects. Correlation analysis identified 7 bacterial species positively correlated withn-butyrate levels, among which the major n-butyrate producer, Faecalibacterium prausnitzii, was particularly underrepresented in CD patients, but not in UC patients. In UC patients, there were inverse correlations between mucin O-glycan levels and the production of SCFAs, such as n-butyrate, suggesting that mucin O-glycans act as an endogenous fermentation substrate for n-butyrate production. Indeed, mucin-fed rodents exhibited enhanced n-butyrate production, leading to the expansion of RORgt+Treg cells and IgA-producing cells in the colonic lamina propria. Importantly, the availability of mucin-associated O-glycans to the microbiota was significantly reduced inn-butyrate-deficient UC patients. Interpretation: Our findings demonstrated that mucin O-glycans facilitate symbiosynthesis of n-butyrate by gut microbiota. Abnormality in the mucin utilization may lead to decreased n-butyrate production in UC patients. Funding Statement: This study was supported by grants from the Japan Society for the Promotion of Science (#16H01369, 17KT0055, and 18H04680 to KH), Health Labour Sciences Research Grant (KH and JK), AMED-Crest (#16gm0000000h0101, 17gm1010004h0102, and 18gm1010004h0103 to KH and JK), AMED (#18ek0109303h0001 to KH and JK), Yakult Foundation (KH), Keio Gijuku Academic Development Funds (KH), The Aashi Grass Foundation, and The Canon Foundation (JK). Declaration of Interests:The authors have declared that no competing interests exist. Ethics Approval Statement: The protocol was approved by the ethics committees of Osaka University (#13165-2), The University of Tokyo (#25-42-1122), Keio University (#150421-1), Shizuoka University (#14-11), and NIBIOHN (#72) prior to subject inclusion. All animal experiments were performed according to protocols approved by the Animal Use Committees of Keio University and Shizuoka University. The rats and mice were maintained in accordance with the guidelines for the care of laboratory animals of Shizuoka University and Keio University, respectively.